Anjali Joshi is an accomplished technology executive and electrical engineer who has held important leadership roles in several high-growth companies. Joshi is an eleven year veteran at Google, Inc. where she served as Vice President for Product Management. During her tenure at Google she led teams on marquee Google products such as Search and adapted cutting edge technologies to solve major healthcare issues in underserved populations. Ms. Joshi received her B.Tech. in Electrical Engineering from IIT Kanpur in 1981. Following it, she went to the USA and obtained her master’s degree in Computer Engineering from the State University of New York and another master’s in Engineering Management from Stanford University.
When: March 15, 2001
“Travails of a Biochemist from old fashioned genomics to corporate management”
Russell Howards, Ph. D.
Russell J. Howard, Ph.D. is the Chief Executive Officer and a co-founder of Maxygen, Inc. At Melbourne University, Victoria, Australia, Dr. Howard received his bachelor’s degree in Biochemistry with honors in 1972 and his Ph.D. on the biochemistry of marine algae in 1975. Dr. Howard began his 18 year career in the field of molecular pathogenesis of malaria in 1976 with post doctoral studies with the immunoparasitology laboratory of Dr. G. F. Mitchell, Walter & Eliza Hall Institute, Melbourne. These studies continued in 1979 with work as a visiting Associate at the National Institute of Allergy and Infectious Diseases at the National Institutes of Health in Bethesda, Maryland. Dr. Howard received tenure at the NIH. In 1988 he created the Laboratory of Infectious Diseases at the DNAX Research Institute of Molecular and Cellular Biology and continued work on antigenic variation in malaria.
In 1992 Dr. Howard joined Affymax Research Institute as Vice President & Director of Cell Biology, and in 1994 he became President & Scientific Director. During this period he led the interdisciplinary team of 200 scientists working on the Affymax combinatorial chemistry and drug discovery platform while continuing to lead studies on malaria molecular pathology. In 1996 Dr. Howard became President and Chief Operating Officer of Maxygen during its incubator phase. In 1997 Maxygen was spun-out of Affymax. Dr. Howard became President and Chief Executive Operator of Maxygen in 1998. Dr. Howard retains his interest in infectious diseases and vaccine discovery and serves currently as Chairman of the USAID Malaria Vaccine Development Program as well as a member of NIH/NIAID malaria vaccine development committee.